first-in-class
small molecule
oncology precision
medicines

Identification
of novel
drug targets

slider3

Inhibitors of
oncogenic
driver RNF31

short
about us

Flindr develops a pipeline of first-in-class small molecule inhibitors for the precision treatment of cancer. We are doing this using our ImmunoGram Drug Discovery Engine, which enables us to discover novel targets in both cancer cells and immune cells.

“we focus on
disruptive cancer science that enables transformative treatments

Knowledge Partners

VIB is an entrepreneurial non-profit research institute, with a clear focus on groundbreaking strategic basic research in life sciences and operates in close partnership with the five universities in Flanders – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University.

Go to partner website

Oncode institute is an independent research institute that unites leading oncology scientists. It is dedicated to cracking the code of cancer and speeding up the translation of discoveries into new diagnostics and treatments for cancer patients.

Go to partner website

Ghent University is a world-class, open, pluralistic and socially engaged university. Ghent university is over 200 years old, offers more than 200 programmes and conducts research in many scientific disciplines. Various disciplines such as biotechnology, aquaculture, microelectronics, history and veterinary medicine are internationally renowned.

Go to partner website

The Netherlands Cancer Institute, founded in 1913, is among the top 10 comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care. Our initiatives to promote excellent translational research have been recognized by the European Academy of Cancer Sciences, when they designated us ‘Comprehensive Cancer Center of Excellence in Translational Research’.

Go to partner website